For patients with Parkinson’s disease receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, according to a study published online Dec. 27 in JAMA Neurology . Andrew J. Lees, M.D., from University College London, and colleagues enrolled 427 patients with PD receiving levodopa therapy who experienced signs of end-of-dose deterioration into a phase 3 trial.